NCT04768881 - Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 12, 2021

Primary Completion Date

September 22, 2023

Study Completion Date

September 22, 2023

Conditions

Locally Advanced Unresectable or Metastatic Melanoma

Interventions

DRUG

Selinexor

Dose and formulation: 80 mg (4 tablets of 20 mg)

DRUG

Pembrolizumab

Dose and formulation: 400 mg (25 milligrams per milliliter \[mg/mL\]) Solution

Trial Locations (13)

Memorial Sloan Kettering Cancer Center, New York

New York Oncology Hematology, Albany

BRCR Global, Plantation

Cleveland Clinic Foundation, Cleveland

OH Care Clinical Trials, Cincinnati

Minnesota Oncology Hematology, Minneapolis

Great Plains Health, North Platte

Texas Oncology - Baylor Sammons Center, Dallas

Texas Oncology-Austin Central, Austin

UCLA, Los Angeles

TOI Clinical Research, Pasadena

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

Rutgers Cancer Institute of New Jersey, New Brunswick